$ZBH

Wire2d ago

Zimmer Biomet Shares Rise After UBS Upgrade

Zimmer Biomet (ZBH) shares rose 4.2% in Tuesday trading after UBS upgraded the stock to buy from sell, and raised the price target to $115 from $89.Trading volume stood at over 2 million shares compared with a daily average of about 2.3 million.Price: $95.34, Change: $+3.27, Percent Change: +3.55%

Research2d ago

UBS Upgrades Zimmer Biomet Holdings to Buy From Sell, Adjusts Price Target to $115 From $89

Zimmer Biomet Holdings (ZBH) has an average rating of overweight and mean price target of $96.95, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $97.15, Change: $+5.08, Percent Change: +5.52%

Research21d ago

BMO Capital Initiates Coverage on Zimmer Biomet With Market Perform Rating, $95 Price Target

Zimmer Biomet (ZBH) has an average rating of hold and mean price target of $95.50, according to analysts polled by FactSet.

$ABBV$ALGN$MRK$PCRX$UNCY$ZBH

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.9% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1.1%.The iShares Biotechnology ETF (IBB) rose 0.2%.In corporate news, Pacira Biosciences (PCRX) has agreed to sell its Iovera cold-therapy pain relief system to Zimmer Biomet (ZBH) for up to $140 million. Pacira shares rose 1%, and Zimmer fell past 6%.Unicycive Therapeutics (UNCY) shares tumbled 40% after it said Tuesday it has received a Complete Response Letter from the US Food and Drug Administration over its resubmitted new drug application for oxylanthanum carbonate for treating hyperphosphatemia in people with chronic kidney disease on dialysis.AbbVie (ABBV) and Merck (MRK) are facing investigations by the China Select Committee of the US House over whether clinical trials conducted in China may have contributed to the country's military capabilities, Reuters reported. AbbVie shares were down 1.3%, and Merck shed nearly 1%.Align Technology (ALGN) shares fell 3% after the European Commission said Tuesday it has opened an antitrust probe to determine whether the company has violated EU competition rules by tying its dental clear aligners to its intra-oral scanners in the European Economic Area.

Dow JonesNasdaq CompositeS&P 500$AMD$AVAV$INTC$MRVL$NKE$NVDA$SNDK$SPGI$STZ$ZBH

Sector Update: Healthcare

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) rose 0.2%.In corporate news, Pacira Biosciences (PCRX) has agreed to sell its Iovera cold-therapy pain relief system to Zimmer Biomet (ZBH) for up to $140 million. Pacira shares rose 1%, and Zimmer fell past 6%.

$PCRX$ZBH

Wire30d ago

Top Midday Decliners

Unicycive Therapeutics (UNCY) said Tuesday it has received a Complete Response Letter from the US Food and Drug Administration over its resubmitted new drug application for oxylanthanum carbonate for treating hyperphosphatemia in patients with chronic kidney disease on dialysis.The letter relates to deficiencies previously identified at third-party manufacturing vendor, the firm said, adding that the FDA inspection of third-party facility did not occur during the resubmission review.Shares sank 37% amid a surge in intraday trading volume to over 17.2 million from a daily average of about 907,000 shares.JPMorgan Chase (JPM), which is running a stock and note offering from Sable Offshore (SOC), has seen limited investor demand for a loan paying 15%, Bloomberg reported Tuesday, citing people familiar with the matter.Sable shares sank 46% as intraday trading volume catapulted to over 45.0 million from a daily average of about 3.8 million.Pacira Biosciences (PCRX) has agreed to sell its Iovera cold-therapy pain relief system to Zimmer Biomet (ZBH) for up to $140 million.Zimmer shares dropped 7.5%, with intraday trading volume of over 2.31 million against a daily average of about 2.34 million.Price: $4.83, Change: $-2.87, Percent Change: -37.27%

$JPM$PCRX$SOC$UNCY$ZBH

US Markets30d ago

Update: Equity Markets Rise Intraday, Poised for Strong Quarterly Gains

(Updates with latest market prices and developments.)US benchmark equity indexes were higher intraday, led by gains in the technology sector, and poised to close out a winning quarter and first half of the year.The Nasdaq Composite was up 1.4% at 26,172.6 after midday Tuesday -- the last trading session of June -- while the S&P 500 rose 0.7% to 7,495.2. The Dow Jones Industrial Average added 0.3% to 52,362.8, following a record-high close in the previous session.The S&P 500 and the Nasdaq were headed for their best quarter in six years, while the Dow was on track for its best quarterly gain since 2022, news outlets reported. The Dow was poised for its best first-half performance since 2021, while the S&P 500 and the Nasdaq were also higher, CNBC reported.Among sectors, tech paced the gainers intraday Tuesday with a 2.2% jump, while real estate saw the steepest decline.Within tech, chip-related stocks mainly led gains, with Intel (INTC) up 7.7%, among the top performers on the S&P 500. Nvidia (NVDA) rose 1.7%, the third-best performer on the Dow. Advanced Micro Devices (AMD), Sandisk (SNDK), and Marvell Technology (MRVL) were also notable gainers on the S&P 500.AeroVironment (AVAV) shares jumped nearly 19% as the drone maker overnight reported stronger-than-expected fiscal fourth-quarter results and issued an upbeat full-year revenue outlook at the midpoint.Zimmer Biomet (ZBH) shares were down 6.9% intraday Tuesday, the worst performer on the S&P 500.Sportswear giant Nike (NKE) and beer and wine company Constellation Brands (STZ) are expected to release their latest quarterly results after the closing bell Tuesday.West Texas Intermediate crude oil was down 1.4% at $69.75 a barrel intraday, while Brent slipped 0.3% to $72.95.WTI and Brent were headed for a steep decline for the month of June as oil prices sold off after the US and Iran agreed to a memorandum of understanding to end their war. In May, crude prices tumbled about 17%."Oil prices traded within a relatively tight range near recent lows while remaining on track for their biggest quarterly decline since the pandemic," Saxo Bank said in a report Tuesday.US special envoys Steve Witkoff and Jared Kushner, who are in Doha, will meet Qatari mediators, not Iranian officials, CNN reported, citing Qatar's Foreign Ministry.US Treasury yields were higher intraday, with the 10-year rate up 3.3 basis points at 4.41% and the two-year rate rising 2.2 basis point to 4.14%.In economic news, US consumer confidence edged higher in June as falling oil prices amid an extended US-Iran ceasefire eased inflation fears, the Conference Board said.US home price growth accelerated annually in April, though the value of homes continued to deteriorate in real terms as high inflation outpaced price gains, S&P Global (SPGI) division S&P Dow Jones Indices said.Gold was little changed at $4,039.40 per troy ounce, while silver climbed 2.1% to $59.86 per ounce.

Asia Markets30d ago

Update: US Equity Indexes Rise as Semiconductors Lift Technology; Crude Oil Slips as Trump's Envoys in Qatar for Indirect Talks

(Updates with index/price moves, macroeconomic data, and company news from the first paragraph.)US equity indexes rose, with the S&P 500 and the Nasdaq Composite set to clock the biggest quarterly gains since Q2 of 2020 amid semiconductor-led gains in technology.The Nasdaq Composite jumped 1.3% to 26,154.1, and the S&P 500 rose 0.7% to 7,490.7 after midday Tuesday. The Dow Jones Industrial Average advanced 0.3% to 52,348.4, heading for the strongest first half in five years.Technology was the standout gainer intraday, followed by industrials. Real estate, consumer staples, and healthcare led the decliners.Of the top 20 stocks with a market capitalization of more than $200 billion, 17 were from the tech sector, according to data compiled by Finviz. Within those tech names, the majority were either semiconductors or semiconductor equipment and materials. The top gainer was Advanced Micro Devices (AMD), trading up 7.7%.Bernstein adjusted the price target for SanDisk (SNDK) shares to $3,000 from $1,700 while maintaining its outperform rating. Shares of SanDisk were up 7.6%, one of the S&P 500 and Nasdaq's top gainers.In geopolitical news, US envoy for the Middle East Steve Witkoff and President Donald Trump's son-in-law Jared Kushner are in Doha to meet Qatari mediators, CNN reported Tuesday, citing Qatar's Foreign Ministry spokesperson. The US duo will not meet with Iranian officials, the report said.The mediators are working as go-betweens for US-Iran talks, which won't include any high-level officials, Qatar's Foreign Ministry spokesman Majed al-Ansari said, according to an Associated Press report.The front-month global benchmark North Sea Brent slipped 1.1% to $73.12 per barrel, and the US West Texas Intermediate fell 1.3% to $69.84 per barrel.Most US Treasury yields rose, with the 10-year up 3.6 basis points to 4.41%. The two-year rate climbed 2.2 basis points to 4.13%.Gold futures edged up 0.1%% to $4,040.5, and silver futures jumped 2.7% to $59.77.In economic news, US job openings rose to 7.594 million in May, according to the Bureau of Labor Statistics, above the 7.296 million openings expected in a Bloomberg-compiled survey and up from the 7.585 million openings reported in April.The Conference Board's measure of consumer confidence rose to 91.2 in June from a downwardly revised 90.6 in May, below the 94.4 expected in a Bloomberg-compiled poll.The Institute for Supply Management's Chicago PMI fell to 56.7 in June from 62.7 in May, compared with the expected 55.1 reading in a Bloomberg-compiled survey.In company news, Air Products and Chemicals (APD) said Tuesday it will not proceed with the Louisiana Clean Energy Project because the expected financial returns do not meet stringent return criteria. The company also said it's finalizing a marketing and distribution agreement with Yara International for renewable ammonia from a green hydrogen project in Saudi Arabia. Shares of Air Products jumped more than 8%, the top gainer on the S&P 500.Pacira Biosciences (PCRX) has agreed to sell its Iovera cold-therapy pain relief system to Zimmer Biomet (ZBH) for up to $140 million. Zimmer shares dropped 7.4%, the worst performer on the S&P 500.

Dow JonesNasdaq CompositeS&P 500$AMD$APD$PCRX$SNDK$ZBH

$ARQT$EVO$IBB$PCRX$XLV$ZBH

Sector Update: Healthcare Stocks Edge Higher Premarket Tuesday

Healthcare stocks were edging higher premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% higher and the iShares Biotechnology ETF (IBB) up 0.4%.Pacira Biosciences (PCRX) has agreed to sell its Iovera cold-therapy pain relief system to Zimmer Biomet (ZBH) for up to $140 million. Pacira BioSciences shares were up more than 3% and Zimmer Biomet stock declined by more than 1% pre-bell.Arcutis Biotherapeutics (ARQT) shares were up more than 1% after the company said the US Food and Drug Administration cleared an expanded use of its Zoryve cream to treat plaque psoriasis in children as young as 2 years old.Evotec (EVO) has expanded its Just-Evotec Biologics services with J.TRAIN, a new offering that lets biopharmaceutical companies use Evotec's manufacturing technology within their own facilities on a turnkey basis, the company said. Evotec shares were up more than 1% pre-bell.

Sector Update: Healthcare

Healthcare stocks were mixed premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.1% lower and the iShares Biotechnology ETF (IBB) up 0.1%.Pacira Biosciences (PCRX) has agreed to sell its Iovera cold-therapy pain relief system to Zimmer Biomet (ZBH) for up to $140 million. Pacira BioSciences shares were up more than 3% and Zimmer Biomet stock declined by more than 2% pre-bell.

$PCRX$ZBH

Stryker's Fundamentals 'Solidly Intact' Despite Cyber Disruption, RBC Says

Stryker's (SYK) fundamentals remain solidly intact despite a recent cybersecurity disruption that could limit upside to the company's 2026 guidance, RBC Capital Markets said in a note Tuesday.Citing comments made by Stryker's competitor, Zimmer Biomet (ZBH), on its earnings call Tuesday, the brokerage said the cyber incident in Q1 did not appear to have translated into any meaningful share loss for Stryker.Zimmer executives said they did not materially benefit from Stryker's operational difficulties due to the cyber incident, while highlighting positive end-market dynamics, with no macro disruption, according to the note.The firm said a healthy orthopedic market with stable demand, steady pricing, reconstruction market growth above 4% and solid hospital capital spending on technology platforms provide a "favorable backdrop" for Stryker, which has resumed full operations following the cyber incident.Stryker has indicated the disruption is "not reasonably likely" to have a material effect on its 2026 outlook, which calls for organic revenue growth of 8% to 9.5%, the firm said.RBC Capital Markets reiterated an outperform rating on Stryker, with a price target of $435.Shares of Stryker were down about 2% in Wednesday trading.Price: $314.80, Change: $-6.63, Percent Change: -2.06%

$SYK$ZBH

Zimmer Biomet Supported by Sales Force Improvements, 2026 Upside Potential, RBC Says

Zimmer Biomet's (ZBH) sales force productivity improvements, stable end markets and continued focus on buybacks remain supportive, though the quarter was weighed by transition-related execution and guidance concerns, RBC Capital Markets said.The company is undergoing go-to-market model adjustments in the US, shifts in emerging markets, aggressive investments in innovation and significant talent and sales force changes. Management categorized 2026 as a "year of transition" and held off on raising full-year revenue guidance despite a "strong" Q1, the brokerage said Tuesday in a note.RBC believes the recent 10% stock decline reflects a lack of core business beat and raise. It also points to concerns over earnings quality, given that most of the EPS beat was driven by a tariff refund. In addition, unchanged revenue guidance implies lower numbers in Q2 to Q4.The firm said the market is also focused on 2027 margin and EPS growth, especially given this year's tariff refund benefit. 2026 guidance has room for a beat and raise, driven by US sales force transition benefits, new product launches and organic growth contribution from Paragon 28 starting in Q2.RBC models 2026 sales of $8.56 billion, near the top end of Zimmer's 1% to 3% growth guidance. It also expects EPS of $8.48, implying 3.5% growth, impacted by acquisition-related dilution and the tariff benefit this year.RBC maintained an outperform rating on Zimmer Biomet with a price target of $101.Shares of Zimmer were down 2.5% in Wednesday trading.Price: $80.76, Change: $-2.04, Percent Change: -2.46%

Bernstein Adjusts Price Target on Zimmer Biomet to $91 From $99, Maintains Market Perform Rating

Zimmer Biomet (ZBH) has an average rating of hold and mean price target of $98.24, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $80.21, Change: $-2.60, Percent Change: -3.13%

Truist Cuts Price Target on Zimmer Biomet Holdings to $92 From $98, Keeps Hold Rating

Zimmer Biomet Holdings (ZBH) has an average rating of hold and mean price target of $97.86 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $80.83, Change: $-1.97, Percent Change: -2.38%

Research93d ago

Research Alert: CFRA Keeps Hold Rating On Shares Of Zimmer Biomet Holdings

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $92 from $100, representing 10.1x our 2027 EPS estimate, a discount to ZBH's five-year average forward P/E of 15.2x. We slightly lift our 2026 EPS view to $8.55 from $8.50 to reflect the Q1 EPS beat. We lower our 2027 EPS to $9.12 from $9.18 as we anticipate some margin pressures. We maintain our Hold rating after Q1 earnings release today as we view 2026 to be a transitional year amid an important leadership change with the long-tenured CFO's departure. Zimmer Biomet reported a better-than-anticipated start to 2026, highlighting healthy end markets, yet management kept the sales guidance intact for 2026, pointing to modest 2.5%-4.5% Y/Y reported growth and 1.0%-3.0% Y/Y organic constant currency growth. ZBH also announced the departure of its CFO, Suketu Upadhyay, who will be joining Incyte as the new CFO. The company has appointed Paul Stellato, its current Controller and Chief Accounting Officer, as the interim CFO, while conducting a search for a permanent successor.